Showing 1791-1800 of 2736 results for "".
- LASEROPTEK Co. Ltd. Taps Dr. Neil Shah as New KOLhttps://modernaesthetics.com/news/laseroptek-co-ltd-taps-dr-neil-shah-as-new-kol/2473433/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit
- It's Camp Time for Dermatologistshttps://modernaesthetics.com/news/its-camp-time-for-dermatologists/2473432/As kids across the country got ready for summer camp, dermatologists flocked to Brooklyn, NY, for their own version of summer camp: Neutrogena’s immersive SkinU Summer Camp. Instead of learning to swim, sliding down a zipline, or playing tennis like kids in camp oft
- CollPlant Achieves Milestone in Dermal Filler Developmenthttps://modernaesthetics.com/news/collplant-achieves-milestone-in-dermal-filler-development/2473431/CollPlant Biotechnologies hit a milestone in the development of a regenerative dermal filler, and this achievement triggers a $10 million payment from AbbVie to CollPlant. In 2021, CollPlant and AbbVie entered into an exclusive worldwide development and commercializatio
- Cartessa Aesthetics Introduces Helix by DEKAhttps://modernaesthetics.com/news/cartessa-aesthetics-introduces-helix-by-deka/2473418/Cartessa Aesthetics is rolling out Helix by DEKA, a fractional ablative CO2 and non-ablative technologies in one device. The US is the first market to make HELIX commercially available. HELIX features pulse shape control for CoolPeel treatment and adds a 1570nm fiber lase
- Analysis: Millennials Drive Spending Growth in a Post-COVID Aesthetics Industryhttps://modernaesthetics.com/news/analysis-millennials-drive-spending-growth-in-a-post-covid-aesthetics-industry/2473413/The aesthetics industry is undergoing a swift transformation. Analysis of data from the last 5 years paints a clear picture of a post-pandemic shift in how the industry is addressing changing demand and the needs of a rapidly evolving customer base, according to market intelligence prov
- Evolus Acquires Exclusive US Distribution Rights to Evolysse Line of Dermal Fillershttps://modernaesthetics.com/news/evolus-acquires-exclusive-us-distribution-rights-to-evolysse-line-of-dermal-fillers/2473412/Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development. Evolus is partnering with Symatese, a privately held French company, to introduce the Evolysse line to its US customers beginning
- Study Shows Preventive Effects and Protective Potential of Astaxanthin on Collagen Damagehttps://modernaesthetics.com/news/study-shows-preventive-effects-and-protective-potential-of-astaxanthin-on-collagen-damage/2473411/A study recently found that Lycored's astaxanthin prevented against collagen damage from neutrophils, discovering its potential to protect collagen and enhance skin health. The study,
- Dr. Shiv Sabesan Named CTO at Cytrellishttps://modernaesthetics.com/news/dr-shiv-sabesan-named-cto-at-cytrellis/2473409/Dr. Shiv Sabesan is Cytrellis Biosystems’ Chief Technology Officer. In his new role, Dr. Sabesan will lead the company's strategy as it continues to advance its proprietary ellacor Micro-Coring technology and expand indications. The technology was
- Aquavit Files Investigational New Drug Application for Intradermal Dermatoxhttps://modernaesthetics.com/news/aquavit-files-investigational-new-drug-application-for-intradermal-dermatox/2473405/Aquavit has filed an Investigational New Drug Application with the U.S Food and Drug Administration (FDA) for Dermatox (aqubotulinumtoxinA), their intradermal injection of botulinum toxin. AqubotulinumtoxinA has already received regulatory approvals in Asia, Sou
- Exosome News: Elevai Labs Scores Grant to Better Characterize Stem Cell-derived Exosomeshttps://modernaesthetics.com/news/elevai-labs-scores-grant-to-better-characterize-stem-cell-derived-exosomes/2473403/Elevai Labs is partnering with Dr. Stanislav Sokolenko’s Lab at Dalhousie University in Nova Scotia, Canada to better characterize Elevai 's stem cell-derived exosomes thanks to a non-repayable grant from the Mitacs Accelerate Grants Program (“Mitacs”).